{"DataElement":{"publicId":"6930176","version":"1","preferredName":"Index Lesion Response irRC Measurable Response Category","preferredDefinition":"The disease response in the largest tumor lesion targeted by therapy using the Immune-Related Response Criteria (irRC).","longName":"IDXLRSP","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6927200","version":"1","preferredName":"Disease Response Domain Index Lesion Measurable Disease Response","preferredDefinition":"A domain for disease response evaluations._The largest tumor lesion targeted by therapy._Capable of being measured._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"6608777v1.0:6927198v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6608777","version":"1","preferredName":"Disease Response Domain","preferredDefinition":"A domain for disease response evaluations.","longName":"C107097","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response Domain","conceptCode":"C107097","definition":"A domain for disease response evaluations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6DD03A-0CB9-71AE-E053-F662850AB42C","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"ONEDATA","dateModified":"2019-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6927198","version":"1","preferredName":"Index Lesion Measurable Disease Response","preferredDefinition":"The largest tumor lesion targeted by therapy.:Capable of being measured.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C110961:C37894:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Index Lesion","conceptCode":"C110961","definition":"The most clinically significant tumor lesion targeted by therapy. The lesion is typically the largest or highest graded of the tumor foci detected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Measurable","conceptCode":"C37894","definition":"Capable of being measured.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"924E74A9-6111-4CA1-E053-F662850A7947","latestVersionIndicator":"Yes","beginDate":"2019-09-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-11","modifiedBy":"ONEDATA","dateModified":"2019-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"924E74A9-6122-4CA1-E053-F662850A7947","latestVersionIndicator":"Yes","beginDate":"2019-09-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-11","modifiedBy":"COOPERM","dateModified":"2020-06-04","changeDescription":"Created for CDSIC aligned NCI Standard CRFs. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6160013","version":"1","preferredName":"irRC Measurable Response Category","preferredDefinition":"Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. (Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20.)_Capable of being measured._Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent._A grouping of items based on some commonality or by user defined characteristics.","longName":"6160013v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"4","maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"irCR","valueDescription":"irCR (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161693","version":"1","preferredName":"irCR (Immune-Related Response Criteria)","longName":"6161693","preferredDefinition":"Complete disappearance of all lesions (whether measurable or not, and no new lesions); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Complete Response","conceptCode":"C148193","definition":"Complete disappearance of all lesions (whether measurable or not, and no new lesions); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0B50-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F533A-F808-5967-E053-F662850A365F","beginDate":"2018-04-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"irPD","valueDescription":"irPD (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161694","version":"1","preferredName":"irPD (Immune-Related Response Criteria)","longName":"6161694","preferredDefinition":"Increase in tumor burden greater than or equal to 25 percent relative to nadir (minimum recorded tumor burden); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Progressive Disease","conceptCode":"C148196","definition":"Increase in tumor burden greater than or equal to 25 percent relative to nadir (minimum recorded tumor burden); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0B75-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F533A-F812-5967-E053-F662850A365F","beginDate":"2018-04-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"irPR","valueDescription":"irPR (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161695","version":"1","preferredName":"irPR (Immune-Related Response Criteria)","longName":"6161695","preferredDefinition":"Decrease in tumor burden greater than or equal to 50 percent relative to baseline confirmed by a consecutive assessment at least 4 weeks after first documentation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Partial Response","conceptCode":"C148194","definition":"Decrease in tumor burden greater than or equal to 50 percent relative to baseline confirmed by a consecutive assessment at least 4 weeks after first documentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0B9A-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F533A-F81C-5967-E053-F662850A365F","beginDate":"2018-04-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"irSD","valueDescription":"irSD (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161696","version":"1","preferredName":"irSD (Immune-Related Response Criteria)","longName":"6161696","preferredDefinition":"Not meeting criteria for irCR or irPR, in absence of irPD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Stable Disease","conceptCode":"C148195","definition":"Not meeting criteria for irCR or irPR, in absence of irPD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0BBF-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691CB836-559C-0AB1-E053-F662850A01FA","beginDate":"2017-10-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"NE","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3855538","version":"1","preferredName":"Unevaluable","longName":"3855538","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F3FD8B-328D-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F4496-0BE4-378D-E053-F662850AA125","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"Not done","valueDescription":"Not Done","ValueMeaning":{"publicId":"2568055","version":"1","preferredName":"Not Done","longName":"2568055","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or not been completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D6E4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-01-12","modifiedBy":"REEVESD","dateModified":"2014-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F4496-0BEE-378D-E053-F662850AA125","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6160012","version":"1","preferredName":"Wolchok Solid Tumors 2009 Oncology Response Criteria Measurable Response Category","preferredDefinition":"Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. (Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20.):Capable of being measured.:Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C126051:C37894:C25755:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wolchok Solid Tumors 2009 Oncology Response Criteria","conceptCode":"C126051","definition":"A measure proposed by Wolchok et al. (Clin Cancer Res 2009;15:7412-7420) to determine the extent of an antitumor response to a particular immunotherapeutic agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Measurable","conceptCode":"C37894","definition":"Capable of being measured.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68E24E85-529F-33CF-E053-F662850A96DC","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-02","modifiedBy":"ONEDATA","dateModified":"2018-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"irRC: Immune-Related Response Criteria-2009","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"68E24E85-52B0-33CF-E053-F662850A96DC","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-02","modifiedBy":"KNABLEJ","dateModified":"2018-10-23","changeDescription":"10/23/18 jk chg reg status to Standard for RECIST defined PV list; do not add PVs without checking latest version of guideline.  4/2/18 jk created for DCI study and immune RECIST FG activities.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6921971","version":"1","longName":"CDISC Aligned Collection CDEs","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6921972","version":"1","longName":"RECIST - CDISC Aligned ","context":"NCI Standards"},{"publicId":"6921973","version":"1","longName":"irRC - CDISC Aligned","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Index lesion","type":"Preferred Question Text","description":"Index lesion","url":null,"context":"NCI Standards"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"924CB33E-9EEF-7B9B-E053-F662850AEA1E","latestVersionIndicator":"Yes","beginDate":"2019-09-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-11","modifiedBy":"GDEEN","dateModified":"2023-02-13","changeDescription":"Released. AK 2020-8-31 Created for CDISC aligned NCI Standard CRF task. mc","administrativeNotes":"02.13.23_Set Reg Status to Standard for all CDISC Aligned content_ghd","unresolvedIssues":null,"deletedIndicator":"No"}}